Azurocidin-1 as a mediator of bronchiectasis severity, epithelial defence, and target of dipeptidyl peptidase-1 inhibition: an international, multicohort study

The Lancet Respiratory Medicine · Published 2026-04-24 · DOI 10.1016/s2213-2600(25)00334-0

Free full text

Authors being retrieved — see the publisher record. https://doi.org/10.1016/s2213-2600(25)00334-0

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year

2026

Related articles

• Toxic skies of war · The Lancet Respiratory Medicine · 2026 · Same journal
• Cryobiopsy versus conventional bronchoscopic sampling for peripheral pulmonary lesions (Cryo-RCT): an open-label, parallel-group, randomised trial · The Lancet Respiratory Medicine · 2026 · Same journal
• Challenging dogmata of oxygen therapy in acute childhood illness · The Lancet Respiratory Medicine · 2026 · Same journal
• The PERC-Peds rule: a promising step towards structured pulmonary embolism risk assessment in children · The Lancet Respiratory Medicine · 2026 · Same journal
• Sphaerosymphony: turning air quality data into music · The Lancet Respiratory Medicine · 2026 · Same journal
• Effects of inflammatory phenotypes in acute respiratory distress syndrome on mortality and partitioning of lung and chest wall mechanics in patients in the USA and Canada: a retrospective cohort study · The Lancet Respiratory Medicine · 2026 · Same journal
• Global economic burden attributable to asthma, 2025–50: a global modelling analysis of 154 countries and territories · The Lancet Respiratory Medicine · 2026 · Same journal
• Videolaryngoscopy in tactical environments: a word of caution · The Lancet Respiratory Medicine · 2026 · Same journal
• From the cost of asthma to the economic dividends of asthma control · The Lancet Respiratory Medicine · 2026 · Same journal
• RSV vaccination and immunisation programmes accelerating worldwide · The Lancet Respiratory Medicine · 2026 · Same journal